Kefir alleviates obesity and hepatic steatosis in high-fat diet-fed mice by modulation of gut microbiota and mycobiota: targeted and untargeted community analysis with correlation of biomarkers

Journal of Nutritional Biochemistry

Volumn 44, Issue , 2017, Pages 35-43

  Kim, Dong Hyeon ^a   Kim, Hyunsook ^b   Jeong, Dana ^a   Kang, Il Byeong ^a   Chon, Jung Whan ^a   Kim, Hong Seok ^a   Song, Kwang Young ^a   Seo, Kun Ho ^a  

^a Konkuk University   (South Korea)

^b Hanyang University   (South Korea)

Author keywords

Fatty acid oxidation; Fatty liver disease; Intestinal microbiota; Intestinal mycobiota; Kefir; Obesity

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; KEFIR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TUMOR NECROSIS FACTOR; CHOLESTEROL; PROBIOTIC AGENT;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CANDIDA; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; EPIDIDYMIS FAT; EXPERIMENTAL FATTY LIVER; EXPERIMENTAL OBESITY; FATTY ACID OXIDATION; FECES MICROFLORA; FOOD INTAKE; GENE EXPRESSION; HISTOPATHOLOGY; INTESTINE FLORA; LACTOBACILLUS; LACTOCOCCUS; LIPID BLOOD LEVEL; LIPID DIET; LIPID METABOLISM; LIVER TISSUE; LIVER WEIGHT; MALE; MILK; MOUSE; MYCOBIOTA; NONHUMAN; ORGAN WEIGHT; PROTEIN BLOOD LEVEL; UPREGULATION; YEAST; ANIMAL; BLOOD; C57BL MOUSE; DIET THERAPY; DISEASE MODEL; FATTY LIVER; GENETICS; LIVER; METABOLISM; MICROBIOLOGY; OBESITY; SACCHAROMYCES CEREVISIAE;

ADIPOSITY; ANIMALS; BIOMARKERS; CANDIDA; CHOLESTEROL; CYTOKINES; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; FATTY LIVER; GASTROINTESTINAL MICROBIOME; KEFIR; LACTOBACILLUS; LACTOCOCCUS; LIVER; MALE; MICE; MICE, INBRED C57BL; OBESITY; PPAR ALPHA; PROBIOTICS; SACCHAROMYCES CEREVISIAE;

EID: 85016632422     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2017.02.014     Document Type: Article

References (51)

1. [1] Gerritsen, J., Smidt, H., Rijkers, G.T., de Vos, W.M., Intestinal microbiota in human health and disease: the impact of probiotics. Genes Nutr 6 (2011), 209–240.
2. [2] Ogden, C.L., Carroll, M.D., Kit, B.K., Flegal, K.M., Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA 311 (2014), 806–814.
3. [3] Harris, K., Kassis, A., Major, G., Chou, C.J., Is the gut microbiota a new factor contributing to obesity and its metabolic disorders?. J Obes, 2012, 2012, 879151.
4. [4] World Health Organization, Obesity and overweight. 2007.
5. [5] Kobyliak, N., Conte, C., Cammarota, G., Haley, A.P., Styriak, I., Gaspar, L., et al. Probiotics in prevention and treatment of obesity: a critical view. Nutr Metab 13 (2016), 14–26.
6. [6] Kim, D.H., Chon, J.W., Kim, H., Seo, K.H., Modulation of intestinal microbiota in mice by kefir administration. Food Sci Biotechnol 24 (2015), 1397–1403.
7. [7] Neuschwander-Tetri, B.A., Caldwell, S.H., Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 37 (2003), 1202–1219.
8. [8] Aron-Wisnewsky, J., Gaborit, B., Dutour, A., Clement, K., Gut microbiota and non-alcoholic fatty liver disease: new insights. Clin Microbiol Infect 19 (2013), 338–348.
9. [9] Ekstedt, M., Franzén, L.E., Mathiesen, U.L., Thorelius, L., Holmqvist, M., Bodemar, G., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44 (2006), 865–873.
10. [10] Gkolfakis, P., Dimitriadis, G., Triantafyllou, K., Gut microbiota and non-alcoholic fatty liver disease. Hepatobiliary Pancreat Dis Int 14 (2015), 572–581.
11. [11] Compare, D., Coccoli, P., Rocco, A., Nardone, O.M., de Maria, S., Cartenì, M., et al. Gut–Liver axis: the impact of gut microbiota on non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 22 (2012), 471–476.
12. [12] Kim, H., Kim, D.H., Seo, K.H., Chon, J.W., Nah, S.Y., Bartley, G.E., et al. Modulation of the intestinal microbiota is associated with lower plasma cholesterol and weight gain in hamsters fed chardonnay grape seed flour. J Agric Food Chem 6 (2015), 1460–1467.
13. [13] Seo, K.H., Kim, H., Chon, J.W., Kim, D.H., Nah, S.Y., Arvik, T., et al. Flavonoid-rich chardonnay grape seed flour supplementation ameliorates diet-induced visceral adiposity, insulin resistance, and glucose intolerance via altered adipose tissue gene expression. J Funct Foods 17 (2015), 881–891.
14. [14] Guzel-Seydim, Z.B., Kok-Tas, T., Greene, A.K., Seydim, A.C., Review: functional properties of kefir. Crit Rev Food Sci Nutr 51 (2011), 261–268.
15. [15] Chon, J.W., Kim, H., Song, K.Y., Kim, D.H., Kim, H.S., Yim, J.H., et al. Functional characteristics of kefir as a fermented dairy product: a review. Korean J Dairy Sci Technol 31 (2013), 99–108.
16. [16] Kim, D.H., Chon, J.W., Kim, H., Kim, H.S., Choi, D.S., Hwang, D.G., et al. Detection and enumeration of lactic acid bacteria, acetic acid bacteria and yeast in kefir grain and kefir milk using quantitative real-time PCR. J Food Safety 35 (2015), 102–107.
17. [17] Czerucka, D., Piche, T., Rampal, P., Review article: yeast as probiotics – saccharomyces boulardii. Aliment Pharmacol Ther 26 (2007), 767–778.
18. [18] Kleiner, D.E., Brunt, E.M., van Natta, M., Behling, C., Contos, M.J., Cummings, O.W., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41 (2005), 1313–1321.
19. [19] Tilg, H., Kaser, A., Gut microbiome, obesity, and metabolic dysfunction. J Clin Invest 121 (2011), 2126–2132.
20. [20] Everard, A., Matamoros, S., Geurts, L., Delzenne, N.M., Cani, P.D., Saccharomyces boulardii administration changes gut microbiota and reduces hepatic steatosis, low-grade inflammation, and fat mass in obese and type 2 diabetic db/db mice. MBio 5 (2014), e01011–e01014.
21. [21] Sekirov, I., Russell, S.L., Antunes, C.M., Finlay, B.B., Gut microbiota in health and disease. Physiol Rev 90 (2010), 859–904.
22. [22] Yang, J.Y., Lee, Y.S., Kim, Y., Lee, S.H., Ryu, S., Fukuda, S., et al. Gut commensal Bacteroides acidifaciens prevents obesity and improves insulin sensitivity in mice. Mucosal Immunol, 2016, 10.1038/mi.2016.42 [Epub ahead of print].
23. [23] Ley, R.E., Turnbaugh, P.J., Klein, S., Gordon, J.I., Microbial ecology: human gut microbes associated with obesity. Nature 444 (2006), 1022–1023.
24. [24] Ottman, N., Smidt, H., de Vos, W.M., Belzer, C., The function of our microbiota: who is out there and what do they do?. Front Cell Infect Microbiol 2 (2012), 104–115.
25. [25] Guo, X., Xia, X., Tang, R., Zhou, J., Zhao, H., Wang, K., Development of a real-time PCR method for Firmicutes and Bacteroidetes in faeces and its application to quantify intestinal population of obese and lean pigs. Lett Appl Microbiol 47 (2008), 367–373.
26. [26] Cani, P.D., Delzenne, N.M., The role of the gut microbiota in energy metabolism and metabolic disease. Curr Pharm Des 15 (2009), 1546–1558.
27. [27] Brown, K., DeCoffe, D., Molcan, E., Gibson, D.L., Diet-induced dysbiosis of the intestinal microbiota and the effects on immunity and disease. Forum Nutr 4 (2012), 1095–1119.
28. [28] Gerristen, J., Smidt, H., Rijkers, G.T., de Vos, W.M., Intestinal microbiota in human health and disease: the impact of probiotics. Genes Nutr 6 (2011), 209–240.
29. [29] Wang, J., Tang, H., Zhang, C., Zhao, Y., Derrien, M., Rocher, E., et al. Modulation of gut microbiota during probiotic-mediated attenuation of metabolic syndrome in high fat diet-fed mice. ISME J 9 (2015), 1–15.
30. [30] Neyrinck, A.M., Possemiers, S., Verstraete, W., De Backer, F., Cani, P.D., Delzenne, N.M., Dietary modulation of clostridial cluster XIVa gut bacteria (Roseburia spp.) by chitin–glucan fiber improves host metabolic alterations induced by high-fat diet in mice. J Nutr Biochem 23 (2012), 51–59.
31. [31] Marchesi, J.R., Adams, D.H., Fava, F., Hermes, G.D., Hirschfield, G.M., Hold, G., et al. The gut microbiota and host health: a new clinical frontier. Gut 65 (2016), 330–339.
32. [32] Kersten, S., Integrated physiology and systems biology of PPARα. Mol Metab 3 (2014), 354–371.
33. [33] Braissant, O., Foufelle, F., Scotto, C., Dauca, M., Wahli, W., Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, −beta, and -gamma in the adult rat. Endocrinology 137 (1996), 354–366.
34. [34] Hardwick, J.P., Osei-Hyiaman, D., Wiland, H., Abdelmegeed, M.A., Song, B.J., PPAR/RXR regulation of fatty acid metabolism and fatty acid -hydroxylase (CYP4) isozymes: implications for prevention of lipotoxicity in fatty liver disease. PPAR Res, 2009, 952734.
35. [35] Ikeda, S., Miyazaki, H., Nakatani, T., Kai, Y., Kamei, Y., Miura, S., et al. Up-regulation of SREBP-1c and lipogenic genes in skeletal muscles after exercise training. Biochem Biophys Res Commun 296 (2002), 395–400.
36. [36] Chen, H.L., Tung, Y.T., Tsai, C.L., Lai, C.W., Lai, Z.L., Tsai, H.C., et al. Kefir improves fatty liver syndrome by inhibiting the lipogeneisis pathway in leptin-deficient Ob/Ob knockout mice. Int J Obes (Lond) 38 (2014), 1172–1179.
37. [37] Kersten, S., Seydoux, J., Peters, J.M., Gonzalez, F.J., Desvergne, B., Wahli, W., Peroxisome proliferator-activated receptor a mediates the adaptive response to fasting. J Clin Invest 103 (1999), 1489–1498.
38. [38] Hashimoto, T., Cook, W.S., Qi, C., Yeldandi, A.V., Reddy, J.K., Rao, M.S., Defect in peroxisome proliferator-activated receptor a-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting. J Biol Chem 275 (2000), 28918–28928.
39. [39] Rao, M.S., Kashireddy, P., Musunuri, S., Okonkwo, A., Prevention/reversal of choline deficiency-induced steatohepatitis by a peroxisome proliferator activated receptor a ligand in rats. In Vivo 16 (2002), 145–152.
40. [40] Ip, E., Farrell, G., Hall, P., Robertson, G., Leclercq, I., Administration of the potent PPARα agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice. Hepatology 39 (2004), 1286–1296.
41. [41] Wyder, M.T., Bachmann, H.P., Puhan, Z., Role of selected yeasts in cheese ripening: an evaluation in foil wrapped Raclette cheese. LWT-Food Sci Technol 32 (1999), 333–343.
42. [42] Aloğlu, H.S., Özer, E.D., Öner, Z., Assimilation of cholesterol and probiotic characterisation of yeast strains isolated from raw milk and fermented foods. Int J Dairy Technol 69 (2015), 63–70.
43. [43] Maccaferri, S., Klinder, A., Brigidi, P., Cavina, P., Costabile, A., Potential probiotic Kluyveromyces marxianus B0399 modulates the immune response in Caco-2 cells and peripheral blood mononuclear cells and impacts the human gut microbiota in an in vitro colonic model system. Appl Environ Microbiol 78 (2012), 956–964.
44. [44] Xie, Y., Zhang, H., Liu, H., Xiong, L., Gao, X., Jia, H., et al. Hypocholesterolemic effects of Kluyveromyces marxianus M3 isolated from Tibetan mushrooms on diet-induced hypercholesterolemia in rat. Braz J Microbiol 46 (2015), 389–395.
45. [45] Kurat, C.F., Natter, K., Petschnigg, J., Wolinski, H., Scheuringer, K., Scholz, H., et al. Obese yeast: triglyceride lipolysis is functionally conserved from mammals to yeast. J Biol Chem 281 (2006), 491–500.
46. [46] Underhill, D.M., Iliev, I.D., The mycobiota: interactions between commensal fungi and the host immune system. Nat Immunol 14 (2014), 405–416.
47. [47] Rizzetto, L., De Filippo, C., Cavalieri, D., Mycobiota: micro-eukaryotes inhabiting our body as commensals or opportunistic pathogens. Fungal Genom Biol, 5, 2015, 120.
48. [48] Rosenberg, E., Zilber-Rosenberg, I., Symbiosis and development: the hologenome concept. Birth Defects Res C Embryo Today 93 (2011), 56–66.
49. [49] Turnbaugh, P.J., Ley, R.E., Mahowald, M.A., Magrini, V., Mardis, E.R., Gordon, J.I., An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444 (2006), 1027–1031.
50. [50] Park, H.S., Park, J.Y., Yu, R., Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-α and IL-6. Diabetes Res Clin Pract 69 (2005), 29–35.
51. [51] Younce, C., Kolattukudy, P., MCP-1 induced protein promotes adipogenesis via oxidative stress, endoplasmic reticulum stress and autophagy. Cell Physiol Biochem 30 (2012), 307–320.